

Apl. Prof. Dr. rer. nat. habil. Viktor Magdolen

Director of the Clinical Research Unit
Department of Gynecology and Obstetrics
Technical University of Munich
Ismaninger Str. 22
81675 Munich
viktor.magdolen@tum.de

Biologist, born April 26, 1957 in Munich, Germany
2 children; citizenship: USA

Professional career

- 1977-1988** Study of biological science at the Ludwig-Maximilians-University, Munich: genetics, biochemistry, zoology. Diploma in genetics. Ph.D. thesis: "Characterization of constitutive and inducible promoter structures in yeast"
- 1988-1993** Postdoctoral fellowships:
- Institut für Genetik und Mikrobiologie, Munich (Prof. Dr. W. Bandlow)
- University of California, Berkeley, U.S.A. (Prof. Dr. D. Drubin)
- Max-Planck-Institut für Biochemie, Martinsried (Prof. Dr. F. Lottspeich)
- 1993 - to date** Klinische Forschergruppe der Frauenklinik der Technischen Universität München (Director: Prof. Dr. M. Kiechle)
- 1997** Co-founder of Wilex Biotechnology GmbH (now Heidelberg Pharma AG)
- 2001** *Habilitation* in Experimental Gynecology
- 2001 - to date** Lecturer at the Medical Faculty of the TU München (*Privat-Dozent: 2001 - 2010*)
- 2010** apl. Professor for Experimental Gynecology
- 2014** Guest professor, Université Pierre et Marie Curie (Sorbonne), Paris, Oktober 2014
- 2016** Co-founder of Therawis Diagnostics GmbH (<http://www.therawis.com>)

Focus of research at the Frauenklinik der TU München

- The role of the urokinase / urokinase receptor system in tumor growth, invasion, and metastasis
- Natural and synthetic inhibitors of tumor-associated proteolytic systems
- The tumor biological role of the serine protease family of kallikrein-related peptidases

Research activities

- 191 publications in scientific journals with an "impact factor"-listing
- 38 publications in other scientific journals or books (no abstracts)
- 9 patents (world-wide, EU, or Germany)
- Editor of two book volumes on kallikrein-related peptidases:
Kallikrein-related peptidases.
Volume 1: Characterization, regulation, and interactions within the protease web.
Volume 2: Novel cancer-related biomarkers.
Magdolen, V, Sommerhoff CP, Fritz H, Schmitt M (eds.), De Gruyter, Berlin
- Supervision of 28 completed dissertations (20x Dr. med., 8x Dr. rer. nat.) plus 2 diploma/master theses
- Supervision of students from Greece, Slovenia, Slovakia, Poland, France, Australia, and China within programs supported by the European Union (Madame Curie Training Site Program; Socrates / Erasmus Program), Centre de Coopération Universitaire Franco-Bavarois (CCUFB), the German Academic Exchange Service (DAAD), and the China Scholarship Council (CSC)

- Board member of the multicenter research project SFB 469 der LMU München (2002-2003); "Scientific Advisor", Wilex AG, München (1997 - 2007); Member of the Editorial Board of *Biological Chemistry*; board member of the E.K.Frey-E.Werle Foundation of the Henning L. Voigt Family (since 2011); board member (since 2013) and deputy chairman of the executive board (since 2018) of the HENNER GRAEFF Foundation
- Director of the German-Australian Network on Personalized Cancer Medicine (DAAD; 2013-2016)
- Conference Secretary, 16th International Congress of the International Society for Fibrinolysis and Proteolysis, 2002, München; Organization and Lecturer at the annual "*Winter School on Proteinases and their Inhibitors and Receptors*" in Tiers, Italy (2005 - 2012); Organization of the 3rd Symposium on Kallikreins and Kallikrein-related Peptidases in Munich, September 2009
- External reviewer of dissertations at the Oxford Brookes University, England; Institute Pasteur and Université Pierre et Marie Curie, Paris, France; University of Salzburg, Austria; University of Antwerp, Belgium; Medical Faculty of the TU Dresden, Germany; Medical Faculty of the Albert-Ludwigs-Universität Freiburg, Germany; Macquarie University, Sydney, Australia; University of Cape Town, South Africa
- Reviewer for scientific journals: *Biochim Biophys Acta*; *Biol Chem*; *Biochem Cell Biol*; *Cancer Lett*; *Cancer Res*; *Cancers*; *Carcinogenesis*; *Cell Mol Life Sci*; *Clin Chem Lab Med*; *Curr Med Chem*; *Eur J Biochem*; *Exp Opin Ther Patents*; *FEBS Lett*; *Int J Cancer*; *Int J Gyn Cancer*; *Int J Oncol*; *Oncogene*; *Oncol Rep*; *Oncotarget*; *PLoS One*; *Proteomics*; *Theranostics*; *Thromb Haemost*; *Thrombosis Res*; *Tumour Biol*
- Reviewer for German (*Deutsche Forschungsgemeinschaft [DFG]*, *Dr. Mildred Scheel-Stiftung*, and *Wilhelm Sander-Stiftung*), Austrian (*FWF Wissenschaftsfonds* and *Österreichische Nationalbank [Jubiläumsfonds]*), Belgian (*Research Foundation Flanders [FWO]* and *Industrial Research Fund Antwerp University Association*), French (*French MS Research Society [ARSEP]*), Italian (*Italian Association for Cancer Research [AIRC]*) and Scottish (*Worldwide Cancer Research*) research funding organizations; external assessor for the *National Health and Medical Research Council, Australia*
- Frey-Werle Promotion Prize (E. K. Frey - E. Werle Foundation of the Henning L. Voigt Family) for the contributions covering both basic and clinically oriented studies in the field of the kallikrein-related peptidases (2011)

Funding/collaborative projects (2016 - to date):

Centre de Coopération Universitaire Franco-Bavarois (BayFrance): V. Magdolen, München - C. El Amri, Sorbonne Université, Paris, 2022: *Design and pharmacological evaluation of neuropsin (KLK8) inhibitors as therapeutics and potential diagnosis tools for Alzheimer's disease and associated dementias*

Wilhelm Sander-Stiftung, with H. Bronger, 2020-21: *Proteolytic cleavage of chemokines as novel resistance mechanism towards PARP inhibitors in ovarian cancer*

Bavarian Ministry of Economy, Infrastructure, Transportation and Technology, with M. Kiechle, 2019-22: *Clinical validation of PITX2 DNA methylation to predict outcome in high-risk breast cancer patients*

Deutsche Forschungsgemeinschaft, with H. Bronger, 2018-2021: *Kallikrein-related peptidase 4 (KLK4) as a new target to improve immune intervention in ovarian cancer*

Centro Universitario de Baviera para América Latina (BayLat): V. Magdolen, München - I.P. Ehrenfeld Slater, Universidad Austral de Chile, Valdivia, Chile, 2019: *Development of nanobodies directed to human kallikrein-related peptidase 4 (KLK4): Analysis of its immunomodulatory properties in ovarian cancer*

Centre de Coopération Universitaire Franco-Bavarois (BayFrance): V. Magdolen, München - Y. Courty, Université de Tours, Tours, 2018-19: *Analysis of the clinical relevance of the kallikrein-related peptidase 12 (KLK12) as biomarker in advanced high-grade serous ovarian cancer*

Wilhelm Sander-Stiftung, V. Magdolen, M. Aubele, M.Schmitt, A. Walch, 2016-19: *Clinical relevance and molecular biological analyses of the miRNA-uPA system axis in triple-negative breast cancer*

Cancer Council Queensland, Chief Investigators (CIs): J.A. Clements, D. Loessner, Y. Dong, J.A. Harris, V. Magdolen, 2016-17: *Targeting kallikrein proteases to improve treatment options for ovarian cancer*

Deutscher Akademischer Austauschdienst (DAAD): Strategic Alliances TU Munich - Queensland University of Technology, *Director: V. Magdolen, 2013-2016: German-Australian network on personalized cancer medicine*